Quantcast

Global Protein Therapeutics Market Outlook 2018

March 13, 2014

DUBLIN, March 13, 2014 /PRNewswire/ –

Research and Markets (
http://www.researchandmarkets.com/research/4j8x47/global_protein) has announced the
addition of the “Global Protein Therapeutics Market Outlook 2018″
[http://www.researchandmarkets.com/research/4j8x47/global_protein ] report to their
offering.

(Logo:
http://photos.prnewswire.com/prnh/20130307/600769 )

Protein based therapies have found a prominent place in the biopharmaceutical industry
since the launch of the human insulin product. They have become one of the most effective
clinical methods to treat a wide spectrum of diseases ranging from cancer to metabolic
disorders. The market holds tremendous potential for future growth and it is estimated
that by the end of 2018, it may reach the mark of US$ 165 Billion as new products
(especially monoclonal antibodies in the advanced clinical phase) may enter the sector.

According to this new research report, Global Protein Therapeutics Market Outlook
2018, a large number of market players have been developing monoclonal antibodies (mAbs).
This research has found that mAbs contribute the largest shares in the number of protein
therapeutic products under pipeline. The report, in this context, gives a comprehensive
analysis of the current and future patterns of revenue generation with respect to mAbs and
other segments.

Through in-depth and prudent analysis of the developments taking place at the global
level, the authors have observed that the US holds a dominant position in the global
protein therapeutics market as the country provides a major proportion of the products’
sales. However, the researchers for this report have come up with an analysis that the
future landscape of the market may find positive developments from Asian countries as huge
patients’ population and increasing disposable incomes may turn out to be a win-win
condition for industry participants.

The report also covers an advanced phase drug analysis. This chapter lists all the
protein therapeutics of the major players which are in the third phase of the clinical
trial. This analysis will help the client in understanding the potential market for the
future. It also helps understand the major segments, indications and players in Protein
Therapeutics that will continue to rule the market.

The report takes into account all the key aspects of the worldwide protein
therapeutics market and projects the market during the period 2012-2018. It prudently
analyzes all the industry segments in an effective manner by focusing on major players and
products, recent developments, application support in terms of indications, geographical
performances and last but not the least, current and future market sizes. Moreover, the
report provides a summary of the recent trends that may have an impact on the future
industry performance.

At the end, the key players of the market have been enlisted. A brief business
overview of every player has been provided along with its product portfolio. This is
followed by the recent developments of the player that may impact the market in the
future. Overall, the report will prove to be a complete source of knowledge and analysis
for clients and potential investors.

        Key Topics Covered:

        1. Analyst View

        2. Research Methodology

        3. Global Protein Therapeutics Market

        4. Industry Performance

        5. Advanced Phase Drugs Analysis

        6. Emerging Market Trends

        7. Key Players

Companies Mentioned:

        - Abbott Laboratories
        - Amgen Inc.
        - Biogen Idec Inc.
        - Eli Lilly & Company
        - Johnson & Johnson
        - Merck Serono S.A.
        - Novo Nordisk
        - Pfizer
        - Roche Group
        - Sanofi-Aventis

For more information visit

http://www.researchandmarkets.com/research/4j8x47/global_protein

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net


    Photo: 

http://photos.prnewswire.com/prnh/20130307/600769

SOURCE Research and Markets


Source: PR Newswire



comments powered by Disqus